(BHC) Bausch Health Companies - Ratings and Ratios

Exchange: NYSE • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA0717341071

Gastroenterology, Dermatology, Neurology, Ophthalmology, Aesthetics

Pharmaceuticals
Market Cap in USD: 2,749m

IPO / Inception: 1994-03-29
12m vs SPY: -18.8%

EPS (Earnings per Share)

EPS CAGR: -46.98%
EPS Trend: -26.0%

Last SUE: -3.49
Qual. Beats: 0

Revenue

Rev. CAGR: -20.89%
Rev. Trend: -13.3%

Last SUE: -4.00
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	53.7%
Value at Risk 5%th	74.8%
Relative Tail Risk	-15.39%

Reward TTM
Sharpe Ratio	0.20
Alpha	-17.83
CAGR/Max DD	-0.02

Character TTM
Hurst Exponent	0.530
Beta	0.898
Beta Downside	1.606

Drawdowns 3y
Max DD	59.28%
Mean DD	28.05%
Median DD	27.90%

Description: BHC Bausch Health Companies January 14, 2026

Bausch Health Companies Inc. (NYSE:BHC) is a diversified specialty pharma and medical-device firm headquartered in Laval, Canada. It markets products across gastroenterology, hepatology, neurology, dermatology, generic and OTC drugs, aesthetic devices, and eye-care. The business is organized into five reporting segments: Salix (GI therapeutics), International (branded, generic, OTC, and aesthetic devices outside the U.S.), Solta Medical (aesthetic devices), Diversified (neurology, dermatology, generic, and dental products), and Bausch + Lomb (vision-care, ophthalmic surgery, and pharma). The company rebranded from Valeant Pharmaceuticals in July 2018.

According to the FY 2023 Form 10-K, BHC generated $2.5 billion in total revenue, with the Salix segment contributing roughly 30 % and Bausch + Lomb about 25 %. The firm carries a net debt of $5.2 billion, yielding a debt-to-EBITDA ratio near 4.0×-a level that exceeds the industry median of ~2.5× and may constrain cash-flow flexibility. Free cash flow turned positive in Q4 2023 after a multi-year deficit, driven by higher margins on specialty GI drugs and incremental sales of vision-care lenses, which benefit from an aging-population tailwind and rising myopia prevalence worldwide. However, the company’s exposure to generic pricing pressure and ongoing litigation risk adds downside uncertainty.

Given the mixed balance-sheet profile and sector dynamics-particularly strong growth in aesthetic procedures and vision-care demand-investors should closely monitor pipeline progress in the GI franchise and the execution of cost-containment initiatives. For a deeper quantitative view, the ValueRay platform offers a granular breakdown of BHC’s valuation metrics.

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (362.0m TTM) > 0 and > 6% of Revenue (6% = 495.6m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA 0.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 17.61% (prev 8.92%; Δ 8.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 1.51b > Net Income 362.0m (YES >=105%, WARN >=100%)

Net Debt (19.68b) to EBITDA (4.79b) ratio: 4.11 <= 3.0 (WARN <= 3.5)

Current Ratio 1.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (373.1m) change vs 12m ago 1.28% (target <= -2.0% for YES)

Gross Margin 81.55% (prev 70.87%; Δ 10.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 30.97% (prev 35.70%; Δ -4.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.14 (EBITDA TTM 4.79b / Interest Expense TTM 3.13b) >= 6 (WARN >= 3)

Altman Z'' 0.06

(A) 0.05 = (Total Current Assets 6.24b - Total Current Liabilities 4.79b) / Total Assets 26.80b

(B) -0.36 = Retained Earnings (Balance) -9.55b / Total Assets 26.80b

(D) -0.03 = Book Value of Equity -839.2m / Total Liabilities 26.44b

Total Rating: 0.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 51.27

1. Piotroski 2.50pt

2. FCF Yield 4.83%

3. FCF Margin 13.14%

4. Debt/Equity -37.24

5. Debt/Ebitda 4.11

6. ROIC - WACC (= 6.29)%

7. RoE -38.20%

8. Rev. Trend -13.29%

9. EPS Trend -25.95%

What is the price of BHC shares?

As of January 16, 2026, the stock is trading at USD 7.45 with a total of 1,232,838 shares traded.
Over the past week, the price has changed by -6.56%, over one month by +5.07%, over three months by +20.60% and over the past year by -4.10%.

Is BHC a buy, sell or hold?

Bausch Health Companies has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold BHC.

Strong Buy: 0
Buy: 1
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the BHC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	7.4	-0.3%
Analysts Target Price	7.4	-0.3%
ValueRay Target Price	8	7.8%

BHC Fundamental Data Overview January 12, 2026

P/E Trailing = 7.6392
P/E Forward = 1.7532
P/S = 0.2741
P/B = 18.7773
P/EG = 0.6315
Revenue TTM = 8.26b USD
EBIT TTM = 3.57b USD
EBITDA TTM = 4.79b USD
Long Term Debt = 20.46b USD (from longTermDebt, last quarter)
Short Term Debt = 578.4m USD (from shortTermDebt, last quarter)
Debt = 21.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.68b USD (from netDebt column, last quarter)
Enterprise Value = 22.46b USD (2.75b + Debt 21.02b - CCE 1.31b)
Interest Coverage Ratio = 1.14 (Ebit TTM 3.57b / Interest Expense TTM 3.13b)
EV/FCF = 20.70x (Enterprise Value 22.46b / FCF TTM 1.08b)
FCF Yield = 4.83% (FCF TTM 1.08b / Enterprise Value 22.46b)
FCF Margin = 13.14% (FCF TTM 1.08b / Revenue TTM 8.26b)
Net Margin = 4.38% (Net Income TTM 362.0m / Revenue TTM 8.26b)
Gross Margin = 81.55% ((Revenue TTM 8.26b - Cost of Revenue TTM 1.52b) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 69.80%)
Tobins Q-Ratio = 0.84 (Enterprise Value 22.46b / Total Assets 26.80b)
Interest Expense / Debt = 9.52% (Interest Expense 2.00b / Debt 21.02b)
Taxrate = 17.89% (39.0m / 218.0m)
NOPAT = 2.93b (EBIT 3.57b * (1 - 17.89%))
Current Ratio = 1.30 (Total Current Assets 6.24b / Total Current Liabilities 4.79b)
Debt / Equity = -37.24 (negative equity) (Debt 21.02b / totalStockholderEquity, last quarter -564.4m)
Debt / EBITDA = 4.11 (Net Debt 19.68b / EBITDA 4.79b)
Debt / FCF = 18.14 (Net Debt 19.68b / FCF TTM 1.08b)
Total Stockholder Equity = -947.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.36% (Net Income 362.0m / Total Assets 26.80b)
RoE = -38.20% (negative equity) (Net Income TTM 362.0m / Total Stockholder Equity -947.6m)
RoCE = 18.28% (EBIT 3.57b / Capital Employed (Equity -947.6m + L.T.Debt 20.46b))
RoIC = 14.27% (NOPAT 2.93b / Invested Capital 20.53b)
WACC = 7.98% (E(2.75b)/V(23.77b) * Re(9.23%) + D(21.02b)/V(23.77b) * Rd(9.52%) * (1-Tc(0.18)))
Discount Rate = 9.23% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.07%
[DCF Debug] Terminal Value 70.30% ; FCFF base≈1.05b ; Y1≈691.8m ; Y5≈315.6m
Fair Price DCF = N/A (negative equity: EV 6.19b - Net Debt 19.68b = -13.49b; debt exceeds intrinsic value)
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: -25.95 | EPS CAGR: -46.98% | SUE: -3.49 | # QB: 0
Revenue Correlation: -13.29 | Revenue CAGR: -20.89% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.70 | Chg30d=-0.064 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=4.20 | Chg30d=+0.031 | Revisions Net=+1 | Growth EPS=+7.4% | Growth Revenue=+3.4%

Additional Sources for BHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle